ThermoGenesis Holdings, Inc. (NASDAQ:THMO – Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 400 shares, a drop of 93.0% from the August 15th total of 5,700 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 71,200 shares, the days-to-cover ratio is currently 0.0 days.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of THMO. Virtu Financial LLC acquired a new position in shares of ThermoGenesis during the second quarter valued at $52,000. Renaissance Technologies LLC increased its holdings in shares of ThermoGenesis by 306.3% during the third quarter. Renaissance Technologies LLC now owns 156,000 shares of the company’s stock valued at $39,000 after purchasing an additional 117,600 shares during the period. Raymond James & Associates acquired a new position in shares of ThermoGenesis during the first quarter valued at $66,000. Two Sigma Investments LP acquired a new position in shares of ThermoGenesis during the first quarter valued at $40,000. Finally, Two Sigma Securities LLC acquired a new position in shares of ThermoGenesis during the first quarter valued at $37,000. 4.71% of the stock is owned by institutional investors and hedge funds.
ThermoGenesis Price Performance
Shares of NASDAQ THMO opened at $1.18 on Friday. ThermoGenesis has a 1-year low of $1.03 and a 1-year high of $14.40. The business’s fifty day moving average price is $1.28 and its two-hundred day moving average price is $1.84.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of ThermoGenesis in a research note on Friday, August 11th.
ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.
- Five stocks we like better than ThermoGenesis
- What to Know About Investing in Penny Stocks
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- 3 Small Caps With Big Return Potential
- Shutterstock is the Value Stock they don’t want you to know about
- Video Game Stocks: How to Invest in Gaming
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with MarketBeat.com's FREE daily email newsletter.